We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Merck & Co. (MRK) plans to complete its $430 million acquisition of Inspire Pharmaceuticals Inc. (ISPH) on Monday after its tender offer for the target's shares got a warm reception from...
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today financial results for the first quarter ended March 31, 2011, reporting a net loss of $17.6 million or ($0.21) per...
Merck & Co.'s (MRK) earnings per share (excluding special items) for the first quarter of 2011 came in at 92 cents, well above the Zacks Consensus Estimate of 84 cents and the...
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) today announced that the waiting period under the...
Merck & Co. Inc. (MRK) is all set to announce its first quarter 2011 results on April 29, 2011, before the opening bell. The Zacks Consensus Estimate for the quarter is $0.84 per share...
Inspire Pharmaceuticals, Inc. (Nasdaq: ISPH) announced today that its annual meeting of stockholders scheduled for May 6, 2011 will be postponed indefinitely due to the recently...
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the commencement of the tender offer for all outstanding shares of Inspire Pharmaceuticals...
The Law Offices of Vincent Wong are investigating the Board of Directors of Inspire Pharmaceuticals, Inc. (Nasdaq: ISPH) for possible breaches of fiduciary duty and other...
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Inspire Pharmaceuticals, Inc. (“Inspire” or...
Weiss & Lurie, a national class action and shareholder rights law firm with offices in New York City and Los Angeles, is investigating possible breaches of fiduciary duty and...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions